News & Opinion

Covering the life sciences inside and out

Most Recent

Glutamate fuels brain tumor growth

By | September 4, 2001

Glutamate is one of the principal neurotransmitters in the brain, but in excess can be highly neurotoxic. In September Nature Medicine Takahiro Takano and colleagues from the New York Medical College, Valhalla, New York, show that in addition to being neurotoxic, glutamate release from glioma cells also promotes growth of malignant gliomas.Takano et al. used bioluminescence to detect glutamate release from freshly prepared brain slices. They found that implanted glioma cells continue to secrete

0 Comments

throughput SIN-ning

By | September 4, 2001

A new expression cloning method based on SIN replicon particles from the Sindbis alphavirus promises high-throughput mammalian expression cloning.

0 Comments

Gene profiling of immune communications

By | September 3, 2001

Early after bacterial invasion dendritic cells express IL-2, providing activation signals greatly enhancing both T and B cell responses.

0 Comments

Setback for UK Synchrotron facilities, as new head takes over

By | September 3, 2001

The closure of the Daresbury synchrotron for emergency repairs emphasises the need for more of these facilities.

0 Comments

Transplastomic tomatoes

By | September 3, 2001

Plastid genome engineering has created transgenic tomatoes, paving the way for the development of appetizing edible vaccines.

0 Comments

Uncovering the secret to human longevity

By | August 31, 2001

One or more genes on chromosome 4 seem to influence who will live to a ripe old age.

0 Comments

Viral killer

By | August 31, 2001

The ability to selectively kill cells lacking normal p53 activity is an attractive anti-cancer strategy. In the August 30 Nature, Kenneth Raj and colleagues from the Swiss Institute for Experimental Cancer Research (ISREC) suggest that adeno-associated virus (AAV) could be employed as a 'hired assassin' (Nature 2001, 412:914-917).They found that AAV induced apoptosis of p53-deficient osteosarcoma cells, but induced cell-cycle arrest (in G2 phase) in cells expressing p53. None of the proteins enc

0 Comments

Not much in common

By | August 30, 2001

A comparison of the Celera and Ensembl transcriptomes examines how many predicted genes they have in common.

0 Comments

The first tissue specific angiogenic mitogen

By | August 30, 2001

VEGF is a newly identified molecule that is an angiogenic mitogen selective for endocrine gland endothelium.

0 Comments

An alternative for toll pathway

By | August 29, 2001

Toll-like receptor 4 uses the TIRAP cytoplasmic adapter protein as an alternative route to induce immune responses.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise
RayBiotech